HIV PrEP Q&A Episode 5
Q&A on HIV PrEP: Episode 5 on Transgender Individuals and Racial and Ethnic Minority Men Who Have Sex With Men Part 2

Released: November 21, 2023

Aniruddha (Anu) Hazra
Aniruddha (Anu) Hazra, MD
Ofole Mgbako
Ofole Mgbako, MD

Activity

Progress
1
Course Completed

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

  • Data on drug–drug interactions between PrEP options and gender-affirming hormone therapy
  • Contributing factors to inequities in PrEP uptake for Black and Latino individuals
  • Data on FTC/TAF PrEP for transgender individuals
  • How to decide whether to do an oral lead-in before starting injectable cabotegravir PrEP
  • Time to effectiveness after starting PrEP 
  • PrEP resources available for transgender communities, especially regarding stigma
  • Integration of PrEP with gender-affirming hormone therapy
  • Strategies to increase PrEP uptake, specifically in the south
  • Counseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEP
  • Involving PrEP navigators in the care of people receiving PrEP
  • Supporting PrEP adherence and retention in care
  • The use of DoxyPEP in transgender individuals receiving PrEP